Xcorporeal Osake

Xcorporeal EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Xcorporeal (XCRP) 12.8.2026 päivämäärällä on −31,79 M USD.

EBITDA

−31,79 MUSD

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Xcorporeal on 2026 −31,79 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Xcorporeal oli 2025 - USD. Se laskee % matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Xcorporeal Osakeanalyysi

Mitä Xcorporeal tekee? Xcorporeal Inc is an American medical technology company specialized in the development and marketing of innovative medical devices. The company was founded in 2002 and is headquartered in Los Angeles, California. The company operates in the field of extracorporeal therapy, where blood is cleansed outside the body. The goal is to rid the body of toxins and excess fluids when the kidneys or liver are not functioning properly. Xcorporeal Inc's business model is based on the development and marketing of extracorporeal therapy devices. The company aims to lead in the field of renal replacement therapy, blood purification, and soluble sepsis treatment. In this context, Xcorporeal Inc is a pioneer in the field of portable hemodialysis devices, which allow patients to receive continuous kidney function treatment. The devices are designed to be easy to use and provide patients with mobility and quality of life. Xcorporeal Inc offers a variety of products tailored to the needs of patients and medical personnel. The portable hemodialysis device FloWatch is one of Xcorporeal Inc's most well-known products. It allows patients to perform treatment at home, providing them with more flexibility and self-determination. Additionally, Xcorporeal Inc has also developed a solution for the treatment of sepsis. Soluble Sepsis Therapy (SST) is a groundbreaking procedure in which blood is pumped through a special filter technology to remove dangerous toxins and inflammatory substances from the blood. Xcorporeal Inc currently operates two divisions focused on other applications of extracorporeal therapy. The first division focuses on the development of devices for blood purification and fighting infections. The second division is involved in the development of medical instruments for use in research and development. Overall, Xcorporeal Inc has the potential to change the face of extracorporeal therapy. With its innovative products and pioneering spirit in the field of portable hemodialysis devices, the company has shown that it is capable of transforming the market and revolutionizing the way extracorporeal therapy is practiced. Xcorporeal on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Xcorporeal osakkeesta

Yhtiön Xcorporeal EBITDA (Tulos ennen korkoja, veroja ja poistoja) on −31,79 M USD vuonna 2026.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Xcorporeal:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n USD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Xcorporeal historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Xcorporeal

Kaikki tunnusluvut — Xcorporeal